Patent intelligence · US
US 9568476
Diagnosis and treatment of breast cancer
Diagnosis and treatment of breast cancer
Patent details — US 9568476
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2017
- Expiration
- Feb 9, 2037
- Claims
- 17
- CPC classes
- A61K, A61K31/4196, A61K31/5685
Quick answer
US 9568476 (Diagnosis and treatment of breast cancer) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/4196, A61K31/5685
More from THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9568476?
US 9568476 (Diagnosis and treatment of breast cancer) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9568476?
THE REGENTS OF THE UNIVERSITY OF MICHIGAN is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9568476 expire?
Our index shows an expiration date of Feb 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.